SEC Tracker
Get the app

Boundless Bio BOLD

Boundless Bio reported a net loss of $5.36 million

Boundless Bio (BOLD) filed a 10-Q with the SEC on Nov 10, 2026, 7:06 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $5.36 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.23 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $34.91 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Boundless Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$6.2M−$24.38M+75%
Net income−$5.36M−$23.69M+77%
Operating cash flow−$10.88M−$20.97M+48%
Cash$34.91M$20.21M+73%

Data on this page was fetched . The filing on SEC.gov is the record.